Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Trevor Doyle is active.

Publication


Featured researches published by Trevor Doyle.


Molecular Pharmacology | 2013

D1-D2 Dopamine Receptor Synergy Promotes Calcium Signaling via Multiple Mechanisms

Lani S. Chun; R. Benjamin Free; Trevor Doyle; Xi Ping Huang; Michele L. Rankin; David R. Sibley

The D1 dopamine receptor (D1R) has been proposed to form a hetero-oligomer with the D2 dopamine receptor (D2R), which in turn results in a complex that couples to phospholipase C–mediated intracellular calcium release. We have sought to elucidate the pharmacology and mechanism of action of this putative signaling pathway. Dopamine dose-response curves assaying intracellular calcium mobilization in cells heterologously expressing the D1 and D2 subtypes, either alone or in combination, and using subtype selective ligands revealed that concurrent stimulation is required for coupling. Surprisingly, characterization of a putative D1-D2 heteromer-selective ligand, 6-chloro-2,3,4,5-tetrahydro-3-methyl-1-(3-methylphenyl)-1H-3-benzazepine-7,8-diol (SKF83959), found no stimulation of calcium release, but it did find a broad range of cross-reactivity with other G protein–coupled receptors. In contrast, SKF83959 appeared to be an antagonist of calcium mobilization. Overexpression of Gqα with the D1 and D2 dopamine receptors enhanced the dopamine-stimulated calcium response. However, this was also observed in cells expressing Gqα with only the D1R. Inactivation of Gi or Gs with pertussis or cholera toxin, respectively, largely, but not entirely, reduced the calcium response in D1R and D2R cotransfected cells. Moreover, sequestration of Gβγ subunits through overexpression of G protein receptor kinase 2 mutants either completely or largely eliminated dopamine-stimulated calcium mobilization. Our data suggest that the mechanism of D1R/D2R–mediated calcium signaling involves more than receptor-mediated Gq protein activation, may largely involve downstream signaling pathways, and may not be completely heteromer-specific. In addition, SKF83959 may not exhibit selective activation of D1-D2 heteromers, and its significant cross-reactivity to other receptors warrants careful interpretation of its use in vivo.


PLOS Neglected Tropical Diseases | 2015

Dopamine Receptor Antagonists as New Mode-of-Action Insecticide Leads for Control of Aedes and Culex Mosquito Vectors

Andrew B. Nuss; Karin F.K. Ejendal; Trevor Doyle; Jason M. Meyer; Emma G. Lang; Val J. Watts; Catherine A. Hill

Background New mode-of-action insecticides are sought to provide continued control of pesticide resistant arthropod vectors of neglected tropical diseases (NTDs). We previously identified antagonists of the AaDOP2 D1-like dopamine receptor (DAR) from the yellow fever mosquito, Aedes aegypti, with toxicity to Ae. aegypti larvae as leads for novel insecticides. To extend DAR-based insecticide discovery, we evaluated the molecular and pharmacological characteristics of an orthologous DAR target, CqDOP2, from Culex quinquefasciatus, the vector of lymphatic filariasis and West Nile virus. Methods/Results CqDOP2 has 94.7% amino acid identity to AaDOP2 and 28.3% identity to the human D1-like DAR, hD1. CqDOP2 and AaDOP2 exhibited similar pharmacological responses to biogenic amines and DAR antagonists in cell-based assays. The antagonists amitriptyline, amperozide, asenapine, chlorpromazine and doxepin were between 35 to 227-fold more selective at inhibiting the response of CqDOP2 and AaDOP2 in comparison to hD1. Antagonists were toxic to both C. quinquefasciatus and Ae. aegypti larvae, with LC50 values ranging from 41 to 208 μM 72 h post-exposure. Orthologous DOP2 receptors identified from the African malaria mosquito, Anopheles gambiae, the sand fly, Phlebotomus papatasi and the tsetse fly, Glossina morsitans, had high sequence similarity to CqDOP2 and AaDOP2. Conclusions DAR antagonists represent a putative new insecticide class with activity against C. quinquefasciatus and Ae. aegypti, the two most important mosquito vectors of NTDs. There has been limited change in the sequence and pharmacological properties of the DOP2 DARs of these species since divergence of the tribes Culicini and Aedini. We identified antagonists selective for mosquito versus human DARs and observed a correlation between DAR pharmacology and the in vivo larval toxicity of antagonists. These data demonstrate that sequence similarity can be predictive of target potential. On this basis, we propose expanded insecticide discovery around orthologous DOP2 targets from additional dipteran vectors.


Journal of Medicinal Chemistry | 2014

Discovery, Optimization, and Characterization of Novel D2 Dopamine Receptor Selective Antagonists

Jingbo Xiao; R. Benjamin Free; Elena Barnaeva; Jennie Conroy; Trevor Doyle; Miller Bn; Marthe Bryant-Genevier; Mercedes K. Taylor; Xin Hu; Andrés E. Dulcey; Noel Southall; Marc Ferrer; Steve Titus; Wei Zheng; David R. Sibley; Juan J. Marugan

The D2 dopamine receptor (D2 DAR) is one of the most validated drug targets for neuropsychiatric and endocrine disorders. However, clinically approved drugs targeting D2 DAR display poor selectivity between the D2 and other receptors, especially the D3 DAR. This lack of selectivity may lead to undesirable side effects. Here we describe the chemical and pharmacological characterization of a novel D2 DAR antagonist series with excellent D2 versus D1, D3, D4, and D5 receptor selectivity. The final probe 65 was obtained through a quantitative high-throughput screening campaign, followed by medicinal chemistry optimization, to yield a selective molecule with good in vitro physical properties, metabolic stability, and in vivo pharmacokinetics. The optimized molecule may be a useful in vivo probe for studying D2 DAR signal modulation and could also serve as a lead compound for the development of D2 DAR-selective druglike molecules for the treatment of multiple neuropsychiatric and endocrine disorders.


Psychopharmacology | 2015

(-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling

Julie Meade; R. Benjamin Free; Nicole Miller; Lani S. Chun; Trevor Doyle; Amy E. Moritz; Jennie Conroy; Val J. Watts; David R. Sibley

Rationale(−)-Stepholidine is a tetrahydroberberine alkaloid that is known to interact with dopamine receptors and has also been proposed as a novel antipsychotic agent. Its suggested novelty lies in the fact that it has been proposed to have D1-like receptor agonist and D2-like receptor antagonist properties. Thus, it might be effective in treating both positive and negative (cognition) symptoms of schizophrenia. However, its activity on specific dopamine receptor subtypes has not been clarified, especially with respect to its ability to activate D1-like receptors.ObjectivesWe wished to examine the affinity and functional activity of (−)-stepholidine at each of the human dopamine receptor subtypes expressed in a defined cellular environment.MethodsD1–D5 dopamine receptors were stably expressed in cell lines and their interactions with (−)-stepholidine were examined using radioligand binding and various functional signaling assays. Radioligand binding assays were also performed using bovine striatal membranes.Results(−)-Stepholidine exhibited high (nM) affinity for D1 and D5 receptors, somewhat lower (two- to four-fold) affinity for D2 and D3 receptors, and low micromolar affinity for D4 receptors. Functionally, (−)-stepholidine was ineffective in activating G protein-mediated signaling of D1-like and D2 receptors and was also ineffective in stimulating β-arrestin recruitment to any dopamine receptor subtype. It did, however, antagonize all of these responses. It also antagonized D1–D2 heteromer-mediated Ca2+ mobilization. Radioligand binding assays of D1-like receptors in brain membranes also indicated that (−)-stepholidine binds to the D1 receptor with antagonist-like properties.Conclusions(−)-Stepholidine is a pan-dopamine receptor antagonist and its in vivo effects are largely mediated through dopamine receptor blockade with potential cross-talk to other receptors or signaling proteins.


Journal of Pharmacology and Experimental Therapeutics | 2014

Evaluation of AaDOP2 receptor antagonists reveals antidepressants and antipsychotics as novel lead molecules for control of the yellow fever mosquito, Aedes aegypti

Jason M. Conley; Jason M. Meyer; Andrew B. Nuss; Trevor Doyle; Sergey N. Savinov; Catherine A. Hill; Val J. Watts

The yellow fever mosquito, Aedes aegypti, vectors disease-causing agents that adversely affect human health, most notably the viruses causing dengue and yellow fever. The efficacy of current mosquito control programs is challenged by the emergence of insecticide-resistant mosquito populations, suggesting an urgent need for the development of chemical insecticides with new mechanisms of action. One recently identified potential insecticide target is the A. aegypti D1-like dopamine receptor, AaDOP2. The focus of the present study was to evaluate AaDOP2 antagonism both in vitro and in vivo using assay technologies with increased throughput. The in vitro assays revealed AaDOP2 antagonism by four distinct chemical scaffolds from tricyclic antidepressant or antipsychotic chemical classes, and elucidated several structure-activity relationship trends that contributed to enhanced antagonist potency, including lipophilicity, halide substitution on the tricyclic core, and conformational rigidity. Six compounds displayed previously unparalleled potency for in vitro AaDOP2 antagonism, and among these, asenapine, methiothepin, and cis-(Z)-flupenthixol displayed subnanomolar IC50 values and caused rapid toxicity to A. aegypti larvae and/or adults in vivo. Our study revealed a significant correlation between in vitro potency for AaDOP2 antagonism and in vivo toxicity, suggesting viability of AaDOP2 as an insecticidal target. Taken together, this study expanded the repertoire of known AaDOP2 antagonists, enhanced our understanding of AaDOP2 pharmacology, provided further support for rational targeting of AaDOP2, and demonstrated the utility of efficiency-enhancing in vitro and in vivo assay technologies within our genome-to-lead pipeline for the discovery of next-generation insecticides.


Parasites & Vectors | 2016

Comparative pharmacological characterization of D1-like dopamine receptors from Anopheles gambiae, Aedes aegypti and Culex quinquefasciatus suggests pleiotropic signaling in mosquito vector lineages

Catherine A. Hill; Trevor Doyle; Andrew B. Nuss; Karin F.K. Ejendal; Jason M. Meyer; Val J. Watts


Archive | 2013

Discovery, optimization, and characterization of a novel series of dopamine D2 versus D3 receptor selective antagonists

Jingbo Xiao; R. Benjamin Free; Elena Barnaeva; Jennie Conroy; Trevor Doyle; Marthe Bryant-Genevier; Mercedes K. Taylor; Noel Southall; Xin Hu; Marc Ferrer; Steve Titus; Wei Zheng; David R. Sibley; Juan J. Marugan


The FASEB Journal | 2016

Identifying new players and pathways involved in receptor-mediated heterologous sensitization of adenylyl cyclase using genome-wide siRNA and BiFC library screening

Trevor Doyle; Karin F.K. Ejendal; Monica Soto Velasquez; Nicholas Santoro; Sulbha Choudhari; Martha J. Larsen; Jyothi Thimmapuram; Chang-Deng Hu; Val J. Watts


The FASEB Journal | 2014

High-throughput screening for novel allosteric modulators of the D1 dopamine receptor (662.4)

Jennie Conroy; R. Free; Trevor Doyle; Noel Southall; Lisa A. Hazelwood; Nicole Miller; Marc Ferrer; David R. Sibley


The FASEB Journal | 2014

Identification of a novel, highly potent D3 dopamine receptor-selective agonist (662.8)

Amy E. Moritz; R. Free; Jennie Conroy; Warren S. Weiner; Trevor Doyle; Noel Southall; Marc Ferrer; Jonathan A. Javitch; Jeffrey Aubé; Kevin J. Frankowski; David R. Sibley

Collaboration


Dive into the Trevor Doyle's collaboration.

Top Co-Authors

Avatar

Jennie Conroy

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

R. Benjamin Free

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Marc Ferrer

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Noel Southall

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Elena Barnaeva

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Jingbo Xiao

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Juan J. Marugan

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Mercedes K. Taylor

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Steve Titus

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Xin Hu

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge